This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (25)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Statistics and Research Methods  • Randomized Controlled Trial  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

American Society of Clinical Psychopharmacology Recommendations

Donald F. Klein, MD; Michael E. Thase, MD; Jean Endicott, PhD; Lawrence Adler, MD; Ira Glick, MD; Amir Kalali, MD; Steven Leventer, PhD; Jeffrey Mattes, MD; Peter Ross; Alexander Bystritsky, MD

Arch Gen Psychiatry. 2002;59:272-278.

The major purpose of this American Society of Clinical Psychopharmacology-sponsored meeting was to identify strategies for more efficiently detecting clinical drug effects, thus reducing the economic and scientific risks of investigating new chemical entities in psychiatric disorders. The meeting consisted of presentations and discussions by experts who repeatedly had difficulty pursuing scientific, public health–relevant goals. Many approaches to improving the detection of potentially beneficial agents were reviewed. In this article, we discuss technically feasible study improvements. The scope of inquiry included identifying means of shifting institutional and regulatory assumptions and processes, even to the point of seeking appropriate national incentives.

From the New York State Psychiatric Institute, New York (Drs Klein and Endicott); University of Pittsburgh Medical Center and Western Psychiatric Institute and Clinic, Pittsburgh, Pa (Dr Thase); Clinical Insights, Glen Burnie, Md (Dr Adler); Stanford University School of Medicine, Stanford, Calif (Dr Glick); Quintiles Inc, San Diego, Calif, and the University of California, Irvine (Dr Kalali); Vela Pharmaceuticals, Lawrenceville, NJ (Dr Leventer); Psychopharmacology Research of Princeton, Princeton, NJ (Dr Mattes); the American Society of Clinical Psychopharmacology Inc and the National Foundation for Depressive Illness, New York (Mr Ross); and the University of California, Los Angeles (Dr Bystritsky). Although all authors have extensive contacts with industry, the focus of this article is methodological.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Not in Our Methods, but in Our Ignorance
Paul Leber
Arch Gen Psychiatry. 2002;59(3):279-280.
EXTRACT | FULL TEXT  

Out of the Box
Alan J. Gelenberg
Arch Gen Psychiatry. 2002;59(3):281.
EXTRACT | FULL TEXT  

From Clinical Trial to Prescription
William T. Carpenter, Jr
Arch Gen Psychiatry. 2002;59(3):282-285.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain
Dworkin et al.
Neurology 2005;65:S7-S19.
ABSTRACT | FULL TEXT  

Effect Size of Symptom Status in Withdrawal of Typical Antipsychotics and Subsequent Clozapine Treatment in Patients With Treatment-Resistant Schizophrenia
Pickar and Bartko
Am. J. Psychiatry 2003;160:1133-1138.
ABSTRACT | FULL TEXT  

Not in Our Methods, but in Our Ignorance
Leber
Arch Gen Psychiatry 2002;59:279-280.
FULL TEXT  

Out of the Box
Gelenberg
Arch Gen Psychiatry 2002;59:281-281.
FULL TEXT